早期炎症性关节炎患者的感染风险:来自英国大型前瞻性观察队列研究的结果
基于英国国家早期炎症性关节炎审计的前瞻性观察队列,纳入2018至2023年英格兰和威尔士新诊断类风湿关节炎成人患者17472例,评估初始传统合成改善病情抗风湿药(csDMARD)和糖皮质激素(CS)与严重感染(SI)风险的关系。以甲氨蝶呤(MTX)为基础的策略较其他csDMARD与SI风险降低相关(校正HR 0.72,95%CI 0.63-0.82);糖皮质激素在未校正模型中与SI风险升高相关,校正后不再显著(校正HR 0.99,95%CI 0.87-1.12)。
要点
- 以MTX为基础的策略较其他csDMARD与严重感染风险降低相关(校正HR 0.72,95%CI 0.63-0.82)。
- 糖皮质激素与严重感染的关联在校正混杂后不再显著(校正HR 0.99,95%CI 0.87-1.12)。
- 年龄增长、吸烟、合并症、血清阳性及高DAS28与严重感染发生率升高相关。
核心结论
- 以MTX为基础的治疗方案较其他csDMARD策略与严重感染风险降低相关。
- 诊断时患者层面和疾病相关因素是新型类风湿关节炎患者严重感染的重要预测因素。
研究设计与样本
- 观察性队列研究,纳入2018至2023年英格兰和威尔士新诊断类风湿关节炎的成人患者,数据来自国家早期炎症性关节炎审计。
- 共纳入17472例患者,其中10997例接受以MTX为基础的策略,4540例接受其他csDMARD,13680例接受糖皮质激素。
- 主要结局为严重感染事件,定义为需住院的感染或导致死亡的感染;次要分析单独评估严重感染相关死亡。
- 采用Cox比例风险模型计算风险比(HR),主要预测因素为初始治疗策略,并校正混杂因素。
主要发现
- 共发生1307例严重感染事件,发病率为每100人年3.02(95%CI 2.86-3.19);严重感染相关死亡311例,发病率为每100人年0.69(95%CI 0.61-0.77)。
- 以MTX为基础的策略较其他csDMARD与严重感染事件风险降低相关(校正HR 0.72,95%CI 0.63-0.82)。
- 糖皮质激素在未校正模型中与严重感染事件风险升高相关,校正模型中该关联不再显著(校正HR 0.99,95%CI 0.87-1.12)。
- 年龄增长、当前或既往吸烟(相对于不吸烟)、合并症、血清阳性及基于28关节计数的高DAS28均与严重感染发生率升高相关。
- 基线DAS28每增加1个单位,严重感染事件风险增加10%。
关键数值与推荐
- 严重感染定义为需住院的感染或导致死亡的感染。
- 以MTX为基础的策略较其他csDMARD与严重感染风险降低相关(校正HR 0.72,95%CI 0.63-0.82)。
- 糖皮质激素与严重感染风险的关联在校正后不再显著(校正HR 0.99,95%CI 0.87-1.12)。
- 基线DAS28每增加1个单位,严重感染事件风险增加10%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify risk of serious infections (SI) according to initial conventional synthetic DMARDs (csDMARD) and CS, in patients recruited to the National Early Inflammatory Arthritis Audit. METHODS: An observational cohort study was used, including adults in England and Wales with new diagnoses of RA between 2018 and 2023. The main outcome was SI events, defined as infections requiring hospitalization/or resulting in death. Secondary analyses evaluated SI-related mortality alone. Hazard ratios (HR) were calculated using cox proportional hazards models. Primary predictor was initial treatment strategy, with confounder adjustments. RESULTS: A total of 17 472 patients were included, of whom 10 997 were on MTX-based strategies, 4540 on other csDMARDs and 13 680 received CS. There were 1307 SI events, corresponding to incidence rates (IR) per 100 person-years of 3.02 (95% CI 2.86-3.19) and 311 cases of SI-related mortality (IR 0.69, 95% CI 0.61-0.77). MTX-based strategies were associated with reduced risk of SI events compared with other csDMARDs (adjusted HR 0.72, 95% CI 0.63-0.82). In unadjusted models, CS was associated with higher risk of SI events, but in adjusted models this association was no longer significant (adjusted HR 0.99, 95% CI 0.87-1.12). Increasing age, being a current/or ex-smoker (relative to non-smoker), having a comorbidity, being seropositive and having high DAS based on 28 joint count (DAS28) were all associated with increased incidence of SI. One unit increase in baseline DAS28 increases the risk of SI event by 10%. CONCLUSION: MTX-based regimens associated with a reduced risk of SI compared with other strategies. Patient-level and disease-related factors at diagnosis are important predictors of SI in individuals with new RA.
引用
- Adas MA, Bechman K, Russell MD, et al. Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort study. Rheumatology (Oxford). 2025. PMID: 40471746. doi:10.1093/rheumatology/keaf312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。